๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS

โœ Scribed by Maan, R.; van der Meer, A.J.; Hansen, B.E.; Feld, J.J.; Wedemeyer, H.; Dufour, J.-F.; Zangneh, H.F.; Lammert, F.; Manns, M.P.; Zeuzem, S.; Janssen, H.L.A.; de Knegt, R.J.; Veldt, B.J.

Book ID
122304222
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
54 KB
Volume
60
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Risk factors for hepatocellular carcinom
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
โœ Akinori Kasahara; Norio Hayashi; Kiyoshi Mochizuki; Masahide Takayanagi; Kentaro ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 2 views

To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with

Risk factors for infection during treatm
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
โœ Robert Roomer; Bettina E. Hansen; Harry L. A. Janssen; Robert J. de Knegt ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 136 KB ๐Ÿ‘ 2 views

Neutropenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C virus (HCV) infection is a common cause of dose reductions of peginterferon alfa. These reductions are performed to prevent bacterial and fungal infections, which are common during HCV treatment and can be att